Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Methods in Enzymology|April 6, 2005
Identification and optimization of protein domains for NMR studiesPaul B Card, Kevin H Gardner
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2009
ARNT PAS-B has a fragile native state structure with an alternative beta-sheet register nearby in sequence spaceMatthew R Evans, Paul B Card, Kevin H Gardner
Journal of Molecular Biology|September 27, 2005
Structural basis of ARNT PAS-B dimerization: use of a common beta-sheet interface for hetero- and homodimerizationPaul B Card, Paul J A Erbel, Kevin H Gardner
The Journal of Biological Chemistry|March 28, 2009
Molecular basis of coiled coil coactivator recruitment by the aryl hydrocarbon receptor nuclear translocator (ARNT)Carrie L Partch, Paul B Card, Carlos A Amezcua, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 12, 2003
Structural basis for PAS domain heterodimerization in the basic helix--loop--helix-PAS transcription factor hypoxia-inducible factorPaul J A Erbel, Paul B Card, Ozgur Karakuzu, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancerBarbara Melosky, Rosalyn Juergens, Deanna McLeod, et al.
Journal of the National Cancer Institute|September 8, 2020
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic ReviewHoward Lim, Ravi Ramjeesingh, Dave Liu, et al.
The Oncologist|May 30, 2019
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung CancerBarbara Melosky, Rosalyn Juergens, Vera Hirsh, et al.
ACS Chemical Biology|December 18, 2012
Regulating the ARNT/TACC3 axis: multiple approaches to manipulating protein/protein interactions with small moleculesYirui Guo, Carrie L Partch, Jason Key, et al.
Therapeutic Advances in Medical Oncology|January 17, 2022
Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the linesChristine Simmons, Daniel Rayson, Anil Abraham Joy, et al.
Pageof 2